Agilent Technologies, Inc. $A Shares Bought by Banque Transatlantique SA

Key Points

• Banque Transatlantique SA significantly increased its stake in Agilent Technologies by over 16,000% during the first quarter, acquiring 64,552 additional shares, leading to a total holding of 64,952 shares valued at approximately $7 million.
• Agilent Technologies received upgrades from several Wall Street analysts, with ratings ranging from "buy" to "outperform" and a consensus target price of $139.25.
• CEO Padraig Mcdonnell sold 1,508 shares at an average price of $117.44, marking a 3.87% reduction in his position, leaving him with 37,448 shares valued at about $4.4 million.

Banque Transatlantique SA boosted its holdings in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 16,138.0% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 64,952 shares of the medical research company's stock after buying an additional 64,552 shares during the period. Banque Transatlantique SA's holdings in Agilent Technologies were worth $7,022,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in A. Advisors Asset Management Inc. increased its holdings in Agilent Technologies by 3.9% during the 1st quarter. Advisors Asset Management Inc. now owns 6,835 shares of the medical research company's stock valued at $800,000 after purchasing an additional 258 shares during the period. Alyeska Investment Group L.P. bought a new position in shares of Agilent Technologies during the 1st quarter valued at $25,988,000. Amundi lifted its holdings in shares of Agilent Technologies by 0.8% during the 1st quarter. Amundi now owns 1,096,994 shares of the medical research company's stock valued at $120,307,000 after buying an additional 8,710 shares during the period. Ancora Advisors LLC raised its holdings in Agilent Technologies by 33.6% in the 1st quarter. Ancora Advisors LLC now owns 19,063 shares of the medical research company's stock worth $2,230,000 after purchasing an additional 4,791 shares during the period. Finally, Adage Capital Partners GP L.L.C. increased its stake in Agilent Technologies by 17.8% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 257,278 shares of the medical research company's stock worth $30,096,000 after buying an additional 38,784 shares in the last quarter. Hedge funds and other institutional investors own 87.41% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently commented on A shares. UBS Group lowered their price target on shares of Agilent Technologies from $150.00 to $130.00 and set a "neutral" rating for the company in a report on Thursday, May 29th. Robert W. Baird boosted their target price on shares of Agilent Technologies from $141.00 to $142.00 and gave the company an "outperform" rating in a research report on Thursday, August 28th. JPMorgan Chase & Co. decreased their price objective on shares of Agilent Technologies from $160.00 to $155.00 and set an "overweight" rating for the company in a research report on Thursday, May 29th. Wall Street Zen cut shares of Agilent Technologies from a "buy" rating to a "hold" rating in a research note on Friday. Finally, Barclays reaffirmed an "equal weight" rating and set a $125.00 price objective on shares of Agilent Technologies in a research note on Friday, August 29th. Six equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, Agilent Technologies presently has a consensus rating of "Moderate Buy" and an average price target of $139.25.

Agilent Technologies Stock Performance

Agilent Technologies stock traded up $0.21 during midday trading on Friday, hitting $128.69. 1,633,203 shares of the company's stock were exchanged, compared to its average volume of 1,522,644. Agilent Technologies, Inc. has a 12-month low of $96.43 and a 12-month high of $153.84. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.71 and a current ratio of 2.25. The stock has a market cap of $36.48 billion, a price-to-earnings ratio of 30.21, a price-to-earnings-growth ratio of 4.00 and a beta of 1.24. The firm's 50 day simple moving average is $119.22 and its 200 day simple moving average is $116.19.

Agilent Technologies (NYSE:A - Get Free Report) last released its earnings results on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, hitting the consensus estimate of $1.37. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The company had revenue of $1.74 billion during the quarter, compared to analysts' expectations of $1.67 billion. During the same quarter last year, the business earned $1.32 EPS. The business's revenue was up 10.1% on a year-over-year basis. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Equities research analysts predict that Agilent Technologies, Inc. will post 5.58 EPS for the current year.

Insider Activity at Agilent Technologies

In other news, CEO Padraig Mcdonnell sold 1,508 shares of the business's stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total transaction of $177,099.52. Following the transaction, the chief executive officer directly owned 37,448 shares of the company's stock, valued at approximately $4,397,893.12. The trade was a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.26% of the company's stock.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.